Date: 2012-04-26
Type of information: R&D agreement
Compound: novel small molecule modulators of a priority biological target involved in immune disorders and cancer
Company: Evotec (Germany) Active Biotech (Sweden)
Therapeutic area: Cancer - Oncology - Immune diseases
Type agreement: collaboration
R&D
Action mechanism:
Disease: cancers, immune diseases
Details: Evotec and Active Biotech have extended and expanded their medicinal chemistry collaboration to further advance an existing programme, which has entered the lead optimisation phase. The programme aims to find novel small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. The programme was initiated in 2010 with a high throughput screen followed by extensive hit validation and hit-to-lead activities, leveraging Evotec’s hit identification and integrated medicinal chemistry platforms.
Financial terms: No financial details are disclosed.
Latest news:
